According to VCBeat, recently, Predicine has raised ￥100M in Series B1 round, led by Kangjun Capital, with participation from existing investors Highlight Capital and Sangel Capital. Proceeds from the latest round will be mainly used for business expansion in the global market, team building and product development.

Founded in 2015, Predicine is a molecular insight company developing genomic profiling tests and robust algorithms for cancer diagnostics and monitoring in U.S. and China. Predicine has successfully developed a new generation of highly sensitive "gene radar" for the detection of RNA and DNA based on liquid biopsy technology and algorithm model, and built a closed-loop genetic testing system and intelligent medical data platform of blood, urine and tissues affected by tumors.

Predicine has CAP-accredited and CLIA-certified laboratories in Shanghai California that provides one-stop service and the overall solution of biomarkers accurate diagnosis, bioinformatics and medical big data for customers at home and abroad, including seven of the world's top ten pharmaceutical companies, in their clinical trials.

Through five liquid biopsy products, Predicine has realized the whole-process management of treatment for tumors in clinical trials, personalized medicine and early screening, and has established the medicine big data platform for precision medicine.

Sangel Capital is a leading investment firm with enormous influence in China dedicated to innovative VC investment on Life Science and Bio-Tech based startups. Sangel Capital provides various resources and services for startup companies, such as funds, proof of concept, product development, market research, business plan development, management, and capital operation.

HLC is a health industry focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.) and consumer health (hospital chains, personal care, etc.).